Track market-moving stories before they get noisy

Vertex Pharmaceuticals (VRTX - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Over the past month, shares of this drugmaker have returned -1.5%, compared to the Zacks S&P 500 composite's +1.4% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Vertex falls in, has lost 0.5%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

Vertex is expected to post earnings of $4.92 per share for the current quarter, representing a year-over-year change of +2.5%. Over the last 30 days, the Zacks Consensus Estimate has changed +1.6%.

For the current fiscal year, the consensus earnings estimate of $18.9 points to a change of +2.7% from the prior year. Over the last 30 days, this estimate has changed +0.4%.

For the next fiscal year, the consensus earnings estimate of $20.61 indicates a change of +9.1% from what Vertex is expected to report a year ago. Over the past month, the estimate has changed +0.7%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Vertex is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of Vertex, the consensus sales estimate of $3.4 billion for the current quarter points to a year-over-year change of +10.6%. The $13.22 billion and $14.67 billion estimates for the current and next fiscal years indicate changes of +10.1% and +11%, respectively.

Last Reported Results and Surprise HistoryVertex reported revenues of $3.33 billion in the last reported quarter, representing a year-over-year change of +12.5%. EPS of $4.73 for the same period compares with $4.52 a year ago.

Compared to the Zacks Consensus Estimate of $3.23 billion, the reported revenues represent a surprise of +3.32%. The EPS surprise was -1.25%.

Over the last four quarters, Vertex surpassed consensus EPS estimates two times. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Vertex is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Vertex. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Nykredit A S purchased a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 204,386 shares of the pharmaceutical company’s stock, valued at approximately $101,525,000. Nykredit A S owned 0.08% of Vertex Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. purchased a new position in Vertex Pharmaceuticals during the second quarter valued at $11,975,849,000. Capital Research Global Investors grew its stake in shares of Vertex Pharmaceuticals by 4.6% in the fourth quarter. Capital Research Global Investors now owns 17,316,344 shares of the pharmaceutical company’s stock worth $7,850,544,000 after acquiring an additional 763,063 shares during the last quarter. State Street Corp increased its holdings in shares of Vertex Pharmaceuticals by 0.7% during the fourth quarter. State Street Corp now owns 11,689,539 shares of the pharmaceutical company’s stock valued at $5,299,569,000 after acquiring an additional 83,539 shares in the last quarter. Capital International Investors increased its holdings in shares of Vertex Pharmaceuticals by 0.9% during the fourth quarter. Capital International Investors now owns 4,733,596 shares of the pharmaceutical company’s stock valued at $2,146,041,000 after acquiring an additional 44,537 shares in the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of Vertex Pharmaceuticals by 49.4% in the 4th quarter. Victory Capital Management Inc. now owns 3,356,766 shares of the pharmaceutical company’s stock worth $1,521,851,000 after purchasing an additional 1,109,200 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Analyst Upgrades and Downgrades VRTX has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, June 28th. Canaccord Genuity Group increased their price target on shares of Vertex Pharmaceuticals from $436.00 to $442.00 and gave the company a “hold” rating in a report on Tuesday, August 4th. Cantor Fitzgerald raised their price target on shares of Vertex Pharmaceuticals from $590.00 to $595.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. The Goldman Sachs Group set a $653.00 price objective on Vertex Pharmaceuticals in a research report on Tuesday, September 1st. Finally, UBS Group increased their target price on Vertex Pharmaceuticals from $545.00 to $585.00 and gave the company a “buy” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $570.83.

Read Our Latest Stock Report on VRTX Vertex Pharmaceuticals Stock Up 0.6% Shares of NASDAQ VRTX opened at $516.34 on Friday. The firm’s 50-day moving average price is $511.35 and its 200-day moving average price is $473.92. The company has a market cap of $131.05 billion, a PE ratio of 30.05, a PEG ratio of 2.25 and a beta of 0.32. Vertex Pharmaceuticals Incorporated has a 52-week low of $374.17 and a 52-week high of $560.25.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing the consensus estimate of $4.74 by ($0.01). The company had revenue of $3.33 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The firm’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same period in the previous year, the firm earned $4.52 earnings per share. As a group, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.69 EPS for the current fiscal year.

Insiders Place Their Bets In other news, EVP Duncan McKechnie sold 1,541 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total value of $799,779.00. Following the transaction, the executive vice president directly owned 11,001 shares in the company, valued at $5,709,519. This trade represents a 12.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $524.99, for a total value of $787,485.00. Following the completion of the sale, the executive vice president directly owned 45,321 shares of the company’s stock, valued at $23,793,071.79. The trade was a 3.20% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 3,637 shares of company stock valued at $1,874,834. Company insiders own 0.20% of the company’s stock.

(Free Report)

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company combines research in human genetics with drug discovery and development.

Vertex is best known for its cystic fibrosis portfolio, which includes CFTR modulator therapies such as Kalydeco, Orkambi, Symdeko and the combination marketed as Trikafta in the United States and Kaftrio in other markets.

Featured Articles Five stocks we like better than Vertex Pharmaceuticals Aeluma’s Selloff Could Be Setting Up Its Next Big Move Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip? The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks The Fed’s Rate Hike Could Backfire If Oil Prices Collapse

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Vertex Pharmaceuticals (VRTX - Free Report) came out with quarterly earnings of $4.73 per share, missing the Zacks Consensus Estimate of $4.79 per share. This compares to earnings of $4.52 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -1.25%. A quarter ago, it was expected that this drugmaker would post earnings of $4.23 per share when it actually produced earnings of $4.47, delivering a surprise of +5.67%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Vertex, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $3.33 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 3.32%. This compares to year-ago revenues of $2.96 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Vertex shares have added about 5.2% since the beginning of the year versus the S&P 500's gain of 9.4%.

What's Next for Vertex?While Vertex has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Vertex was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $4.94 on $3.34 billion in revenues for the coming quarter and $19.15 on $13.06 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Oculis Holding AG (OCS - Free Report) , has yet to report results for the quarter ended June 2026.

This company is expected to post quarterly loss of $0.48 per share in its upcoming report, which represents a year-over-year change of +18.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Oculis Holding AG's revenues are expected to be $0.26 million, down 17.8% from the year-ago quarter.

The first five months of 2026 were rough on Vertex Pharmaceuticals (VRTX 2.22%). The biotech's shares moved in the wrong direction through early June. However, the drugmaker has bounced back in style over the past month, with its stock gaining 10%. Vertex Pharmaceuticals is now up 9% this year and recently hit a fresh 52-week high. Is there more upside left for the stock? Let's find out.

Potential catalysts on the horizon Several recent developments explain why the market is increasingly excited about Vertex Pharmaceuticals' prospects. First, the company recently received a label expansion for Casgevy, a gene-editing medicine for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), two blood-related diseases. Casgevy is now indicated to treat patients as young as two who have TDT or SCD (it was previously approved for people 12 and older).

Image source: The Motley Fool.

This regulatory milestone adds 5,500 patients to Vertex's addressable market, but, even more importantly, it allows patients and their families to treat these diseases before they have had time to significantly impact their lives. Casgevy has not generated much revenue since its 2023 approval. This label expansion should help boost its sales. Second, Vertex Pharmaceuticals is awaiting approval for povetacicept, an investigational medicine for IgA nephropathy (IgAN), a kidney disease. U.S. regulators could give this therapy the green light by the end of November.

Povetacicept would be a key addition to Vertex's lineup. Given the more than 1.5 million IgAN patients worldwide and the medicine's potential approval across other indications, some analysts project it could reach peak sales of about $4.3 billion. Third, Vertex Pharmaceuticals has several other late-stage clinical trial candidates that could make good progress. For instance, the company is developing inaxaplin, a potential therapy for APOL-1-mediated kidney disease, and expects some data readouts later this year.

Lastly, Vertex Pharmaceuticals announced the acquisition of Crinetics Pharmaceuticals (CRNX 0.05%), a biotech company focused on developing medicines for endocrine diseases, for $10 billion in cash. Vertex estimates that this buyout adds more than $5 billion in potential peak annual sales to its lineup. All these developments make Vertex Pharmaceuticals' medium-term prospects attractive.

Today's Change

(

-2.22

%) $

-11.03

Current Price

$

485.47

The core business is still going strong Vertex Pharmaceuticals remains the leader in its core therapeutic area: developing medicines for patients with cystic fibrosis (CF). This rare disease causes thick mucus to form in the lungs, disrupting the airways and leading to chronic infections. Vertex remains the only game in town. It markets the only drugs that treat the underlying causes of CF. Though the biotech has been dominating this area for a long time, business is still good. In the first quarter, Vertex Pharmaceuticals' revenue increased by 8% year over year to $2.99 billion. The company's adjusted earnings per share climbed 10% year over year to $4.47.

Vertex Pharmaceuticals still has a decent patient population to address as it expands into new territories and earns new label expansions, especially for younger patients. The company's core business should remain a growth driver over the next decade, as its most important products won't face patent cliffs until the late 2030s. Even though some pharmaceutical companies are developing competing therapies, all previous attempts have failed. Successes may come, eventually, but that's also why Vertex has diversified its lineup.

The company's newer non-CF approvals, including Casgevy and Journavx, a medicine for acute pain, should start meaningfully contributing to top-line growth within a couple of years. Vertex expects at least $500 million in non-CF revenue this year. That will represent less than 5% of its revenue, but with Casgevy gaining traction thanks to label expansions and Journavx meeting strong demand for non-opioid pain drugs, they should post solid sales growth over the next few years. So, Vertex Pharmaceuticals still has plenty of upside ahead, even though it recently hit a new 52-week high. Investors can safely hold this stock for the long term.

No stock has generated more buzz in recent weeks than Space Exploration Technologies (SPCX +2.69%), more commonly known as SpaceX. That's understandable, considering the space technology and artificial intelligence (AI) innovator conducted the largest initial public offering (IPO) in history.

But buzz doesn't always translate to great returns (as many who bought SpaceX shares after its post-IPO surge are finding out). While SpaceX gets the headlines, some smart investors are loading up on another stock instead -- Vertex Pharmaceuticals (VRTX +6.13%).

Image source: Getty Images.

Greater market dominance than SpaceX One key reason investors have been attracted to SpaceX is its commanding position in the satellite internet services and rocket launch markets. However, Vertex arguably has greater market dominance in its core arena than SpaceX.

Only five therapies have been approved for addressing the underlying genetic cause of cystic fibrosis (CF), a rare genetic disease that affects an estimated 105,000 people worldwide. Vertex markets all of them, giving the drugmaker a virtual monopoly in the CF indication.

SpaceX will soon have a formidable competitor to its lucrative Starlink business from Amazon (AMZN +0.55%) Leo. Meanwhile, Vertex has little to worry about from challengers at this point. The most advanced experimental therapies that even have a shot at challenging Vertex's blockbuster CF franchise are only in Phase 2 clinical testing. No patent cliff is in sight that would open the door to serious generic threats, either. Vertex's key U.S. and European patents for its most powerful CF drug, Alyftrek, don't expire until 2039.

Today's Change

(

6.13

%) $

30.51

Current Price

$

528.52

CF isn't Vertex's only area of focus. The company has two other products gaining market momentum -- CRISPR gene-editing therapy Casgevy and non-opioid pain medication Journavx. These two therapies together generated roughly 25% of Vertex's product revenue growth in its latest quarter.

Importantly, Vertex's market dominance is much more profitable than SpaceX's. The big biotech company posted adjusted earnings of $4.7 billion last year, compared with SpaceX's net loss of $4.9 billion.

Transformative launches potentially on the way SpaceX completed 167 launches last year with its Falcon 9 rockets and Starship reusable spacecraft. However, Vertex has some potential launches of a different sort on the way that could be transformative.

The U.S. Food and Drug Administration (FDA) is scheduled to make an approval decision for povetacicept in the treatment of immunoglobulin A nephropathy (IgAN) by Nov. 30, 2026. IgAN affects around three times more patients in the U.S. and Europe alone than CF does worldwide. Vertex is also evaluating povetacicept in Phase 2 studies targeting primary membranous nephropathy and generalized myasthenia gravis, which together affect around three times as many patients in the U.S. and Europe as CF does worldwide.

Patient dosing in a late-stage study evaluating zimislecel in treating severe Type 1 Diabetes has resumed after a temporary delay while Vertex performed a manufacturing analysis. It seems likely that the company will file for global regulatory approvals of the therapy next year, assuming the Phase 3 results are positive.

Two other launches could be around the corner as well. Vertex expects to complete patient enrollment in two Phase 3 studies of suzetrigine (Journavx) in diabetic peripheral neuropathy (DPN) by the end of this year. Eventual approval in treating DPN would open up an additional patient population of around 2.5 million for Journavx.

And that's not all. Vertex's pipeline features another late-stage candidate, inaxaplin, which targets APOL1-mediated kidney disease (AMKD). This disease affects around 250,000 people, and there aren't any approved treatments for it.

Risks vs. rewards Every investment comes with potential risks and rewards. Vertex's approved products and promising pipeline offer clear rewards over the next few years. However, the company faces several risks, notably the possibility of regulatory setbacks and clinical failures.

But many investors could reasonably conclude that Vertex's overall risk-reward proposition is more appealing than SpaceX's. That's especially true given each stock's valuation. SpaceX's shares trade at a whopping 56.7 times projected 2026 sales. Vertex's forward price-to-sales multiple is around 10x.

Investing in SpaceX is tantamount to placing a bet on a future that hasn't arrived yet, with that future already baked into the space stock's valuation. Buying Vertex Pharmaceuticals, on the other hand, is more like betting on a future supported by prior clinical results that inspire confidence, with a share price that reflects some uncertainty. The latter seems like the smarter wager.